Flurpiridaz and the Future of Nuclear Cardiology

The recent FDA approval of Flurpiridaz is a game-changer in myocardial perfusion imaging. With its longer half-life, availability of unit dosing and the ability to combine its use with treadmill testing , it has the potential to shift practice patterns away from traditional SPECT and make PET imaging more widely available to patients.

More in Journal of Nuclear Cardiology Compendium: https://www.journalofnuclearcardiology.org/content/jnc_compendium